Core Viewpoint - The stock of 加科思-B (01167) has seen a significant increase, rising over 7% during trading, attributed to a strategic equity transfer agreement with 海松资本 and an industry partner, aimed at optimizing capital allocation and focusing on key oncology pipeline products [1] Group 1: Stock Performance - 加科思-B's stock price increased by 6.12%, reaching 7.8 HKD, with a trading volume of 23.94 million HKD [1] Group 2: Strategic Agreement - 加科思 has signed an equity transfer agreement where 海松资本 will pay a total of 2 billion RMB (1.25 billion RMB upfront and 750 million RMB milestone payment) to acquire 80% of 加科瑞康 [1] - Following the completion of this transaction, 加科思's ownership in 加科瑞康 will decrease to 10% [1] Group 3: Strategic Focus - The transaction aligns with the company's strategy to focus on critical oncology pipeline products, including KRAS, MYC, P53, and tumor immunology [1] - The proceeds from the equity transfer will be used for the research, production, and commercialization of the Pan-KRAS inhibitor and other innovative oncology projects [1]
港股异动 | 加科思-B(01167)盘中涨超7% 公司出售非核心项目 聚焦肿瘤创新药核心管线